Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The influenza diagnostics market is undergoing significant transformations driven by technological advancements, shifting demographics, and evolving healthcare practices. One of the notable trends shaping this market is the increasing adoption of rapid diagnostic tests for influenza. Rapid tests offer the advantage of delivering quick and accurate results, enabling healthcare providers to promptly diagnose and initiate appropriate treatment for patients. The demand for rapid influenza diagnostic tests is expected to continue growing, particularly in settings such as emergency departments, clinics, and point-of-care facilities, where timely diagnosis is crucial for patient management and infection control.
Another key trend in the influenza diagnostics market is the integration of molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), for influenza testing. Molecular diagnostics offer high sensitivity and specificity, allowing for the detection and differentiation of different influenza virus strains. The growing adoption of molecular diagnostic platforms in clinical laboratories and healthcare facilities is expected to drive the market for molecular influenza diagnostics, as these techniques play a vital role in surveillance, outbreak investigation, and the identification of emerging influenza strains.
Additionally, the market is witnessing a trend towards the development of innovative and multiplexed diagnostic assays for respiratory infections, including influenza. Multiplex assays enable the simultaneous detection of multiple respiratory pathogens, such as influenza viruses, respiratory syncytial virus (RSV), and other common respiratory pathogens, in a single test. This trend reflects the need for comprehensive diagnostic solutions that can efficiently identify the causative agents of respiratory illnesses, streamline testing workflows, and optimize resource utilization in healthcare settings.
Furthermore, the convergence of influenza diagnostics with digital health technologies is shaping the market by enabling remote monitoring, telemedicine, and data-driven surveillance of influenza outbreaks. The integration of connected diagnostic devices, telehealth platforms, and data analytics solutions is facilitating real-time tracking of influenza trends, enhancing disease surveillance, and supporting public health efforts to monitor and control influenza transmission.
Moreover, there is a growing focus on the development of point-of-care influenza diagnostic solutions that offer simplicity, portability, and ease of use. Point-of-care tests enable rapid and on-the-spot diagnosis of influenza, empowering healthcare providers to make timely clinical decisions and facilitate appropriate patient management. The demand for user-friendly and decentralized diagnostic tools is expected to drive the market for point-of-care influenza diagnostics, particularly in resource-limited and remote healthcare settings.
In conclusion, the influenza diagnostics market is characterized by the increasing adoption of rapid tests, the integration of molecular diagnostic techniques, the development of multiplexed assays, the convergence with digital health technologies, and the emphasis on point-of-care solutions. These trends are reshaping the landscape of influenza diagnostics, driving innovation, and enhancing the capabilities of healthcare providers to effectively diagnose and manage influenza infections while supporting public health efforts to combat influenza outbreaks.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Opportunities | Startups Explore Untapped Market Potential |
Influenza Diagnostics Market Highlights:
Influenza Diagnostics Market Overview
Market Research Future (MRFR) studied the Influenza Diagnostics Market is expected to reach USD 1.81 Billion by 2032 at CAGR 5.3% during the forecast period 2023-2032.
A contagious respiratory infection induced by several flu viruses is called influenza. Every year, a large number of people is afflicted with seasonal influenza that result in hospitalizations and flu-related deaths of a large number of people, especially the aging patient population.
COVID-19 Analysis
The impact evaluation of the influenza diagnosis market for COVID-19 is recorded in the report. The report details the impact of new policies by governments on the healthcare field due to the pandemic. The outbreak of COVID 19 has detrimental effect on the world health and medical system. The report describes solutions that are deployed to counter the decline in healthcare system of the world. Other major issues are elaborated in detail in the report.
In recognition of patients having COVID-19, flue, and respiratory syncytial virus (RSV) Lucira COVID-19 & Flu Home Test was authorized by the U.S. FDA in February 2023 for emergency use and diagnosis of influenza viruses A and B made by Pfizer Inc. It is an over-the-counter (OTC) at-home diagnostic test.
Aptima SARS-CoV-2/Flue test was launched by Hologic Inc. In October 2022, in Europe and North America as well. This approval will likely result in market growth in both these regions.
Seegene introduced syndromic PCR testing for COVID-19, influenza A/B strains and RSV that should be performed on a routine basis at "selected" points located across the European and Asian markets since August 2022. The campaign is called In-Life PCR which was put in place to counteract spikes in transmission caused by relaxing public health measures against COVID-19 along with other respiratory viruses due to increased travel activities.
In June 2022, Becton Dickinson announced CE marking of its BD MAX Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for the detection of SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV), under IVD directive 98/79/EC.
Influenza Diagnostics Market Trends
DriversGrowing Prevalence of Influenza to Support Market Rise
The growing prevalence of influenza creating the need to deliver effective treatment can favor the expansion of the influenza diagnostic market. In addition, a rise in funding for research in influenza diagnosis can add to the market expansion. The fast-growing demand for quick diagnostic solutions can favor market expansion in the years to come. The increase in awareness about such disease and the introduction of quadrivalent influenza vaccines can drive the influenza diagnostics market in the coming years.
OpportunitiesStartups Explore Untapped Market Potential
The emergence of startups exploring the untapped potential of the market can contribute to the creating of numerous revenue generation pockets for the market by 2023. The introduction of disruptive technologies, such as artificial intelligence, favoring innovations in diagnostic solutions can support the market rise.
RestraintsHike in Medical Care Cost to Inhibit Market Growth
The gradual rise in healthcare expenses and issues with inaccuracy in diagnostic solutions can hinder the influenza diagnostics market rise in the years to come.
Influenza Diagnostics Market Segment Insights
Influenza Diagnostics Type of Flu Insights
The type A flu segment can rise at a substantial pace with decent CAGR. The segment can acquire a USD 954.512 Million influenza diagnostics market share by 2023. The type B flu segment can rise at 8.66% CAGR from 2018 to 2023. The increase in initiatives by the government to curb influenza is likely to boost market growth.
Influenza Diagnostics Test Type Insights
The molecular diagnostic tests segment can exhibit the highest CAGR along the evaluation tenure as physicians are inclined towards accurate diagnostic solutions. The traditional diagnostics segment can also thrive in the approaching years.
Influenza Diagnostics End-User Insights
The point of care testing segment can retain the leading position in the global influenza diagnostics market by 2023. The segment can exhibit decent CAGR through the analysis tenure. An increase in number of clinicals dedicated to diagnosis and treatment of influenza can drive the hospital and clinical laboratories segment growth.
Influenza Diagnostics Regional Insights
Americas Market to Thrive by 2023
In Americas, the influenza diagnostics market can secure 38.0% share of the global market value by 2023. The regional influenza diagnostics market can thrive across the forecast tenure due to increase in prevalence of influenza and the ease of availability of advanced healthcare facilities.
EU Influenza Diagnostics to Gain Momentum
In Europe, the aviation test equipment market can secure the second-largest share of the global market. The rise in count of pharmaceutical companies dealing in exporting their products is also responsible for growth of the regional market. Rise in disease awareness, and extended recommendations by advisory bodies and governmental for vaccination against influenza can contribute to the market upsurge.
APAC Market to Hold Forefront Position
Asia Pacific influenza diagnostics market can secure the forefront position in the global lead. This can be attributed to rapid development in healthcare infrastructure and growing prevalence of endocrinology, lymphatic systems, cardiovascular, and respiratory disorders.
Competitive Landscape
MRFR enlisted renowned companies that are operating in the global influenza diagnostics market. The competitive analysis of the influenza diagnostics market consists of market share analysis, financial analysis, and product benchmarking. Alongside, strategic developments in the market that include mergers & acquisitions, product launches, and joint ventures are also studied by MRFR analysts that can help in understanding regional progress and growth scopes offered by these enterprises.
List of Key Companies Covered in this Report
- Coris BioConcept
- DiaSorin S.p.A
- Alere Inc.
- Lonza
- Ortho-Clinical Diagnostics
- Qiagen
- Wako
- Abbott
- Analytik Jena AG
- Becton, Dickinson and Company,
- Biocartis,
- bioMérieux Inc,
- Cepheid,
- DiaSorin S.p.A., F.
- Hoffmann-La Roche Ltd,
- GenMark Diagnostics, Inc.,
- Luminex Corporation,
- Meridian Bioscience, Inc.,
- Quidel Corporation,
- SA Scientific,
- Thermo Fisher Scientific Inc.
Recent Developments
- February 2023- The Molecular Diagnostic System is a powerful tool for quickly identifying and distinguishing between COVID-19, the flu, and RSV. By taking a single nasal swab or a single nasopharyngeal swab sample, it can analyze the sample and provide results in as little as two hours. This makes it incredibly useful for quickly diagnosing and treating patients with the most appropriate care. Furthermore, the system is highly accurate, meaning that patients can be confident that they are receiving the right diagnosis and treatment. The Molecular Diagnostic System is an invaluable tool in the fight against the spread of infectious diseases like COVID-19, the flu, and RSV.
- January 2021-Labs that are performing Flu SC2 Multiplex Assay recognized by the Centers for Disease Control’s (CDC), which is a single test to diagnose infection caused due to influenza A, SARS-CoV-2, or influenza B, can now use a Promega nucleic acid purification kit and two Promega instruments. Promega is a Wisconsin-based producer of enzymes and other types of molecular biology and biotechnology portfolio
- January 2021-GeneIQ, a Texas-based molecular diagnostics laboratory that offer COVID-19 testing across the country, announced the introduction of combined PCR test for influenza A (Flu A), viruses SARS-CoV-2 (COVID-19), respiratory syncytial virus (RSV), and influenza B (Flu B).
Influenza Diagnostics Market Segmentation
Market analysis, sizing, and forecast of the influenza diagnostics market are covered in the report. The country-level assessment of the market and associated forecasts are explained in the influenza diagnostics market report. The expansion of the influenza diagnostic controlling market dynamics intelligence that includes, market drivers, opportunities, supply chain, restraints, trends, value chain analysis, and Porter’s five forces are studied by MRFR analysts. Patent analysis outlook, Technology trends, and regulatory landscape of the market is detailed in the report to help investors acquire an in-depth understanding of the market and associated activities.
Influenza Diagnostics Type of Flu Outlook
- Type A Flu
- Type B Flu
- Type C Flu
Influenza Diagnostics Test Type Outlook
- Traditional Diagnostic Tests
- Molecular Diagnostic Tests
Influenza Diagnostics End-User Outlook
- Hospitals & Clinical Laboratories
- Point-of-Care Testing
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
